Mazyar Shadman, MD, MPH

Dr. Lipsky presents a second case of a 72-year-old man with symptomatic CLL requiring therapy.

Dr. Shadman presents a case of a 68-year-old woman with symptomatic CLL requiring treatment.

Dr. Shadman addresses when to switch within the BTKi class versus changing mechanism of action.

Dr. Shadman introduces pirtobrutinib, the non-covalent BTKi currently approved as second-line therapy after covalent BTKi exposure.

Dr. Shadman introduces an important practical consideration from Flatiron real-world data examining BTKi discontinuation rates in elderly patients, challenging the notion that older patients with CLL need only one line of therapy.

Dr. Shadman notes that discussions about elderly patients with CLL increasingly focus on patients aged 80 years and older, given the disease's median diagnosis age of 68 to 70 years.

Andrew Lipsky, MD, reviews the ELEVATE-TN trial supporting acalabrutinib approval in frontline CLL, demonstrating superiority over chlorambucil-obinutuzumab.

Dr. Lipsky addresses the framework for interpreting real-world data and cross-trial comparisons in the absence of head-to-head trials.

Dr. Lipsky outlines MRD testing utility across the three major treatment approaches.

Dr Shadman addresses tumor lysis syndrome, a longstanding concern with BCL2 inhibition, in light of the absence of any tumor lysis syndrome events in this study.

Dr. Mazyar Shadman discusses the scientific rationale for combining sonrotoclax with zanubrutinib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Dr Shadman frames the clinical need for treatment mechanisms beyond conventional BTK inhibition in patients with relapsed or refractory B-cell malignancies.

Dr Shadman outlines the key open questions and later-phase data to watch for both programs.

Dr Shadman contextualizes the efficacy of the BTK degrader catadegbrutinib in relapsed or refractory Waldenström macroglobulinemia, where it produced an overall response rate of 83.7%, a major response rate of 76.7%, and a very good partial response rate of 30.2% at a median follow-up of 16.6 months.

Dr Shadman explains how BTK degradation differs mechanistically from BTK inhibition.

Dr Shadman frames the clinical need for treatment mechanisms beyond conventional BTK inhibition in patients with relapsed or refractory B-cell malignancies.

Dr. Shadman explains that high-risk definitions evolve as treatments change.

Dr. Mazyar Shadman introduces the program on first-line CLL therapy in the era of BTK inhibition, joined by Dr. Andrew Lipsky.

Panelists discuss how improving CAR T accessibility through reduced monitoring requirements could strengthen its position against bispecific antibodies in treatment decision-making, emphasizing that access considerations should only influence therapy choice when efficacy and safety are comparable, not when CAR T demonstrates superior outcomes.

Panelists discuss how immune cell–associated neurotoxicity syndrome data mirrors cytokine release syndrome patterns, with 70% of patients experiencing no neurotoxicity, only 5% to 7% developing grade 3 or higher events, and most toxicities occurring early and resolving within 1 week, further supporting arguments for modified monitoring approaches.

Panelists discuss how data from over 1500 patients receiving liso-cel shows consistent cytokine release syndrome (CRS) outcomes between clinical trials and real-world settings, with most CRS events occurring within the first 2 weeks and late-onset events being rare and manageable, supporting potential changes to monitoring protocols.

Panelists discuss how CAR T monitoring requirements have evolved from initially conservative inpatient approaches to more flexible outpatient strategies, exploring ways to reduce the burden of mandatory 30-plus-day proximity requirements while maintaining patient safety and improving treatment accessibility.

Panelists discuss how CAR T cell therapy has transformed lymphoma treatment with multiple FDA-approved products showing 70% to 80% overall response rates and 50% to 60% complete response rates across different B-cell malignancies, while emphasizing the importance of comparing clinical trial data with real-world evidence to understand true efficacy and safety profiles.

Experts discuss future directions and key insights in treating large B-cell lymphoma (LBCL).

Experts discuss safety management and monitoring protocols for liso-cel in treating relapsed/refractory large B-cell lymphoma.

Experts provide a safety summary of the phase 3 TRANSFORM study, highlighting key safety findings for liso-cel in relapsed/refractory large B-cell lymphoma.

Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Experts discuss the impact of manufacturing and treatment timing on patient outcomes for chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL).

Experts discuss patient selection and timing considerations for chimeric antigen receptor T-cell (CAR T) therapy in treating relapsed/refractory large B-cell lymphoma.

Experts discuss long-term efficacy and real-world outcomes with liso-cel in treating relapsed/refractory large B-cell lymphoma.